Actavia Life Sciences, Inc. (RASP)

OTCMKTS · Delayed Price · Currency is USD
0.0040
-0.0285 (-87.69%)
At close: Jul 22, 2024
-83.94%
Market Cap 3.09M
Revenue (ttm) n/a
Net Income (ttm) -406.65K
Shares Out 771.81M
EPS (ttm) -0.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 5,000
Average Volume 14,416
Open 0.0040
Previous Close 0.0325
Day's Range 0.0040 - 0.0040
52-Week Range 0.0004 - 0.0390
Beta -81.43
RSI 45.25
Earnings Date Feb 18, 2025

About Actavia Life Sciences

Actavia Life Sciences, Inc., a leukemia-focused biotechnology company, engages in developing therapeutics for the treatment of acute myeloid leukemia (AML) and other forms of leukemia and lymphoma. It is developing RASP-201, a novel, orally dosed, selective reversible inhibitor of lysine specific demethylase, a pathway that blocks differentiation and confers a poor prognosis to AML; and RASP-301, an NCE for NPM1, currently at the pre-clinical stage to treat refractory AML with reduced toxicity. The company was formerly known as Rasna Therapeuti... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 1
Stock Exchange OTCMKTS
Ticker Symbol RASP
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.